 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4758 News |  |
| «12...49505152535455565758596061» |
- Gazyva (obinutuzumab) / Roche, Biogen
Trial primary completion date: A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation (clinicaltrials.gov) - Jun 2, 2016
P1, N=25, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Jun 2018
- ||| Trial initiation date, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jun 2, 2016
P1/2, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2018 --> Jun 2018 Initiation date: Dec 2015 --> Mar 2016
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial initiation date, Trial primary completion date, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jun 2, 2016
P1/2, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Dec 2015 --> Mar 2016 Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: Oct 2021 --> Jun 2021
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Trial primary completion date, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jun 2, 2016
P1b, N=92, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: Oct 2021 --> Jun 2021 Phase classification: P1/2 --> P1b | Trial primary completion date: Mar 2019 --> Jan 2020
- |||| Enrollment open, Combination therapy: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jun 2, 2016
P1/2, N=86, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1/2 --> P1b | Trial primary completion date: Mar 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- |||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
Trial primary completion date, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 31, 2016
P3, N=450, Recruiting, Sponsor: TG Therapeutics, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2018 --> Sep 2018
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial initiation date, Trial primary completion date: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. (clinicaltrials.gov) - May 26, 2016
P1, N=30, Not yet recruiting, Sponsor: Michael Choi
Trial primary completion date: Mar 2018 --> Sep 2018 Initiation date: Feb 2016 --> Nov 2016 | Trial primary completion date: Feb 2017 --> Nov 2017
- | Zydelig (idelalisib) / Gilead
Trial termination, Combination therapy: Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 19, 2016
P3, N=57, Terminated, Sponsor: Gilead Sciences
Initiation date: Feb 2016 --> Nov 2016 | Trial primary completion date: Feb 2017 --> Nov 2017 Active, not recruiting --> Terminated
- || Velexbru (tirabrutinib) / Ono Pharma, Gilead
Trial primary completion date, Combination therapy: Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies (clinicaltrials.gov) - May 12, 2016
P1, N=320, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Terminated Trial primary completion date: Jun 2017 --> Dec 2018
- || Trial primary completion date, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - May 9, 2016
P1, N=93, Recruiting, Sponsor: Emergent Product Development Seattle LLC
Trial primary completion date: Jun 2017 --> Dec 2018 Trial primary completion date: Jun 2016 --> Dec 2016
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed, Combination therapy: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - May 6, 2016
P3, N=978, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial: CLL2-GiVe: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (clinicaltrials.gov) - May 2, 2016
P2, N=40, Not yet recruiting, Sponsor: University of Ulm
- |||| Calquence (acalabrutinib) / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy: ELEVATE-TN: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment na (clinicaltrials.gov) - Apr 27, 2016
P3, N=510, Recruiting, Sponsor: Acerta Pharma BV
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Dec 2019
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Combination therapy: Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 25, 2016
P2, N=30, Not yet recruiting, Sponsor: University Health Network, Toronto
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Combination therapy: Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 13, 2016
P2, N=20, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- ||| Gazyva (obinutuzumab) / Roche, Biogen
Clinical: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response (clinicaltrials.gov) - Apr 11, 2016
P2, N=120, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Aug 2019 --> Dec 2019 Initiation date: Jun 2015 --> Apr 2016 | Trial primary completion date: Sep 2020 --> Apr 2021
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Combination therapy: BO29562: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=46, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jun 2015 --> Apr 2016 | Trial primary completion date: Sep 2020 --> Apr 2021 Trial primary completion date: Oct 2018 --> Jan 2020
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial primary completion date, Combination therapy: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Apr 6, 2016
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2018 --> Jan 2020 Trial primary completion date: Sep 2017 --> Mar 2018
- ||||| New P1/2 trial, Combination therapy: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Apr 6, 2016
P1/2, N=92, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Apr 1, 2016
P2, N=30, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Sep 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- |||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Trial primary completion date: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 1, 2016
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2023 --> Mar 2023
- ||||| Zydelig (idelalisib) / Gilead
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 22, 2016
P3, N=57, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2023 --> Mar 2023 Recruiting --> Active, not recruiting | N=308 --> 57 | Trial primary completion date: Mar 2019 --> May 2016
- Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Enrollment change, Trial primary completion date, Combination therapy: Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) (clinicaltrials.gov) - Mar 22, 2016
P1, N=46, Recruiting, Sponsor: Infinity Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | N=308 --> 57 | Trial primary completion date: Mar 2019 --> May 2016 N=64 --> 46 | Trial primary completion date: Dec 2017 --> Nov 2021
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 22, 2016
P2, N=45, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=64 --> 46 | Trial primary completion date: Dec 2017 --> Nov 2021 Not yet recruiting --> Recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change: ICLL-07: Phase II Trial GA101 Inbrutinib B CLL (clinicaltrials.gov) - Mar 16, 2016
P2, N=12, Recruiting, Sponsor: French Innovative Leukemia Organisation
Not yet recruiting --> Recruiting N=135 --> 12
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion, Trial primary completion date, Combination therapy: A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) (clinicaltrials.gov) - Mar 8, 2016
P1, N=41, Completed, Sponsor: Genentech, Inc.
N=135 --> 12 Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jan 2013
- ||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
New P2 trial, Combination therapy: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma (clinicaltrials.gov) - Feb 24, 2016
P2, N=98, Not yet recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- Ukoniq (umbralisib) / TG Therap
Trial primary completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 3, 2016
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jan 2013 Trial primary completion date: Feb 2016 --> Aug 2016
- Calquence (acalabrutinib) / AstraZeneca
Enrollment closed, Combination therapy: ACE-CL-003: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (clinicaltrials.gov) - Feb 3, 2016
P1, N=45, Active, not recruiting, Sponsor: Acerta Pharma BV
Trial primary completion date: Feb 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=248, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Phase classification: P1 --> P1/2
- | Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification, Combination therapy: GO29365: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=224, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 Phase classification: P2 --> P1/2
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Phase classification, Combination therapy: BO29562: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=46, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P2 --> P1/2 Phase classification: P1 --> P1/2
- | idasanutlin (RG7388) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Phase classification, Combination therapy: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 Phase classification: P1 --> P1/2
- | Phase classification, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 Phase classification: P1 --> P1/2
- | Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Phase classification, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 Phase classification: P1 --> P1/2
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 2, 2016
P1/2, N=92, Recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1 --> P1/2 Phase classification: P1 --> P1/2
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: FIL-GALILEO: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. (clinicaltrials.gov) - Feb 1, 2016
P2, N=90, Not yet recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 30, 2016
P2, N=32, Active, not recruiting, Sponsor: PrECOG, LLC.
Phase classification: P1 --> P1/2 Recruiting --> Active, not recruiting | N=150 --> 32 | Trial primary completion date: Aug 2017 --> Apr 2016
- | Gazyva (obinutuzumab) / Roche, Biogen
Trial initiation date, Trial primary completion date: Lenalidomide and Obinutuzumab for Previously Untreated CLL (clinicaltrials.gov) - Jan 15, 2016
P1/2, N=25, Not yet recruiting, Sponsor: University of California, San Diego
Recruiting --> Active, not recruiting | N=150 --> 32 | Trial primary completion date: Aug 2017 --> Apr 2016 Initiation date: Apr 2015 --> Feb 2016 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||||| Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
Enrollment open, Combination therapy: UNITY-CLL: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 15, 2016
P3, N=450, Recruiting, Sponsor: TG Therapeutics, Inc.
Initiation date: Apr 2015 --> Feb 2016 | Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- ||| Brukinsa (zanubrutinib) / BeiGene
Enrollment open, Combination therapy: BGB-3111_GA101_Study_001: BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies (clinicaltrials.gov) - Jan 15, 2016
P1, N=86, Recruiting, Sponsor: BeiGene
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Enrollment open, Combination therapy: GO29833: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 4, 2016
P1, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: GO29834: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 4, 2016
P1, N=116, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) (clinicaltrials.gov) - Dec 30, 2015
P2, N=66, Recruiting, Sponsor: German CLL Study Group
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) (clinicaltrials.gov) - Dec 25, 2015
P2, N=66, Active, not recruiting, Sponsor: German CLL Study Group
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients (clinicaltrials.gov) - Dec 25, 2015
P2, N=66, Active, not recruiting, Sponsor: German CLL Study Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy: BO29562: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Dec 16, 2015
P1, N=46, Recruiting, Sponsor: Hoffmann-La Roche
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial initiation date, Combination therapy: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 15, 2015
P1, N=60, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 14, 2015
P2, N=45, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change, Trial primary completion date, Combination therapy: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Dec 10, 2015
P1, N=90, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015 N=70 --> 90 | Trial primary completion date: Jan 2015 --> Nov 2016